Back to Search
Start Over
IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.
- Source :
- Clinical Lymphoma, Myeloma & Leukemia; 2021 Supplement 1, Vol. 21, pS404-S404, 1p
- Publication Year :
- 2021
Details
- Language :
- English
- ISSN :
- 21522650
- Volume :
- 21
- Database :
- Complementary Index
- Journal :
- Clinical Lymphoma, Myeloma & Leukemia
- Publication Type :
- Academic Journal
- Accession number :
- 152099233
- Full Text :
- https://doi.org/10.1016/S2152-2650(21)01912-1